Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor, Michael Haddadin, Vivek Upadhyay, et al.
Blood (2019) Vol. 134, Iss. 8, pp. 678-687
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4238-4251
Open Access | Times Cited: 104
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Emily Y. Jen, Xin Gao, Liang Li, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 3, pp. 532-536
Open Access | Times Cited: 80
Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin
Gabriel K. Griffin, Christopher A.G. Booth, Katsuhiro Togami, et al.
Nature (2023) Vol. 618, Iss. 7966, pp. 834-841
Open Access | Times Cited: 33
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju, Marina Konopleva
Blood Advances (2020) Vol. 4, Iss. 16, pp. 4020-4027
Open Access | Times Cited: 58
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients
Kamel Laribi, Alix Baugier de Materre, Mohamad Sobh, et al.
Blood Advances (2020) Vol. 4, Iss. 19, pp. 4838-4848
Open Access | Times Cited: 58
Sex-BiasedZRSR2Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
Katsuhiro Togami, Sun Sook Chung, Vikas Madan, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 522-541
Open Access | Times Cited: 46
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Kendra Sweet, Anthony S. Stein, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 26, pp. 3032-3036
Open Access | Times Cited: 32
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 567-578
Open Access | Times Cited: 31
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia‐Manero, et al.
Blood Advances (2022) Vol. 6, Iss. 10, pp. 3027-3035
Open Access | Times Cited: 30
Plasmacytoid dendritic cell neoplasms
Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, et al.
Blood Research (2023) Vol. 58, Iss. S1, pp. S90-S95
Open Access | Times Cited: 19
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, et al.
Blood (2021) Vol. 138, Iss. 15, pp. 1373-1377
Open Access | Times Cited: 41
Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies
Shefali Mehra, Justin Taylor
Cells (2024) Vol. 13, Iss. 3, pp. 243-243
Open Access | Times Cited: 5
Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant
Seongseok Yun, Onyee Chan, Daniel Kerr, et al.
Blood Advances (2020) Vol. 4, Iss. 14, pp. 3435-3442
Open Access | Times Cited: 39
Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Qaiser Bashir, Denái R. Milton, Uday Popat, et al.
Bone Marrow Transplantation (2021) Vol. 57, Iss. 1, pp. 51-56
Open Access | Times Cited: 32
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy
Nathaniel R. Wilson, Marina Konopleva, Joseph D. Khoury, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 11, pp. 734-740
Closed Access | Times Cited: 29
Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, et al.
HemaSphere (2023) Vol. 7, Iss. 3, pp. e841-e841
Open Access | Times Cited: 13
Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature
Wei‐Ying Jen, Marina Konopleva, Naveen Pemmaraju
Cancer (2024) Vol. 130, Iss. 13, pp. 2260-2271
Closed Access | Times Cited: 4
Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis
Mohamed A. Kharfan‐Dabaja, Tea Reljic, Hemant S. Murthy, et al.
Clinical Lymphoma Myeloma & Leukemia (2018) Vol. 18, Iss. 11, pp. 703-709.e1
Closed Access | Times Cited: 34
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm
Naseema Gangat, Marina Konopleva, Mrinal M. Patnaik, et al.
American Journal of Hematology (2021) Vol. 97, Iss. 2
Open Access | Times Cited: 26
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics
Ijele Adimora, Nathaniel R. Wilson, Naveen Pemmaraju
Cancer (2022) Vol. 128, Iss. 16, pp. 3019-3026
Closed Access | Times Cited: 17
Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial
Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-4
Closed Access
Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding
Kana Sakamoto, Kengo Takeuchi
Journal of Clinical and Experimental Hematopathology (2025) Vol. 65, Iss. 1, pp. 1-16
Open Access
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm
Danielle Hammond, Naveen Pemmaraju
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 565-574
Closed Access | Times Cited: 24
Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations
Evgenii Shumilov, Paolo Mazzeo, Susanne Ghandili, et al.
Annals of Hematology (2024) Vol. 103, Iss. 5, pp. 1587-1599
Open Access | Times Cited: 3
Blastic Plasmacytoid Dendritic Cell Neoplasm
Éric Deconinck, Tony Petrella, Francine Garnache Ottou
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 491-500
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top